Better outcomes adding enasidenib to azacitidine in mIDH2-AML Presented ByDr Courtney Di Nardo, MD Anderson Cancer Centre, USA TrialPhase 2, AG-221-AML-005 ConferenceEHA 2020 TypePeer-reviewed article 9 September 2020 12:55